Neonatal Glycemia and Neurodevelopmental Outcomes at 2 years

CHYLD · NEJM · 2015

Hypoglycemia was common and often silent: Over half of at-risk infants (54%) had blood glucose < 2.6 mmol/L (< 47 mg/dL), with 1 in 3 episodes detected only on masked CGM. ​No difference in major 2-year neurodevelopmental outcomes: When treated promptly to keep glucose ≥ 2.6 mmol/L, infants with hypoglycemia had similar rates compared to euglycemic peers for: ​Overall neurosensory impairment: 15.7% vs. 10.1% (no statistically significant difference). ​Cognitive scores (Bayley-III): Equivalent (~103 vs. 103). ​Motor scores (Bayley-III): Equivalent (~98 vs. 100). ​Cerebral palsy: Rare in both groups (< 1%). ​Sensory processing delay: Identical rates (~28% vs. 27%). ​Depth and duration did not predict outcome: Lowest glucose level, episode count, and total time < 2.6 mmol/L were not linked to neurosensory deficits in this treated cohort. ​Glucose swings and overshoots caused harm: ​High variability: Wide glucose fluctuations in the first 48 hours nearly doubled the odds of neurosensory impairment and cognitive delay. ​Rebound hyperglycemia: Spending excess time > 4.0 mmol/L (> 72 mg/dL) independently increased impairment risk.

Active screening and treatment targeting a blood glucose threshold of ≥ 2.6 mmol/L prevented an increase in cerebral palsy, major motor disability, or global cognitive delay at 2 years corrected age. However, early 2-year testing does not capture higher-order cortical dysfunctions that emerge later in childhood. Glycemic instability, sharp glucose swings, and rebound hyperglycemia during correction carry greater developmental risk than the depth or duration of hypoglycemia itself when treated promptly.

* Treated cohort & age limit: Reflects actively managed hypoglycemia rather than untreated natural history, while 2-year testing misses subtle executive and visuospatial deficits that appear later.

* CGM lag: Interstitial sensors have a 5–15 minute physiological lag behind plasma glucose during rapid drops, underestimating acute biochemical nadirs.

* Smooth titration protects the brain: Screening and treating to keep blood glucose > 2.6{ mmol/L} (47 mg/dL) prevents overt motor disability, but avoiding wild swings and rebound hyperglycemia is just as critical as fixing the low.